Showing 1 - 10 of 7,118
Persistent link: https://www.econbiz.de/10009687474
may have differential effects that vary by firm size. We use quarterly sales data on UK pharmaceuticals in a dynamic panel …
Persistent link: https://www.econbiz.de/10012903446
In the context of the ongoing debate about an innovation crisis in the pharmaceutical industry, we study the success rates of pharmaceutical R&D projects as a measure of innovative productivity. The empirical literature suggests success rates have been decreasing during recent decades. We...
Persistent link: https://www.econbiz.de/10011773501
Within the last decades, there have been many technological and regulatory changes in the pharmaceutical industry. Some of these developments facilitate the innovative activities of large firms, while others foster small firms. It is therefore surprising that the implications of these changes in...
Persistent link: https://www.econbiz.de/10011844257
Pharmaceutical firms typically enjoy market exclusivity for new drugs from concurrent protection of the underlying invention (through patents) and the clinical trials data submitted for market approval (through data exclusivity). Patent invalidation during drug development renders data...
Persistent link: https://www.econbiz.de/10012064786
How does a firm’s market power in existing products affect its incentives to innovate? We explore this fundamental question using granular project-level and firm-level data from the pharmaceutical industry, focusing on a particular mechanism through which incumbent firms maintain their market...
Persistent link: https://www.econbiz.de/10012818283
Operation Warp Speed (OWS) was a U.S. government-led program to accelerate the development, production, and administration of COVID-19 vaccines. The program cut the typical ten-year timeline needed to develop a new vaccine down to ten months and began vaccinating vulnerable populations within a...
Persistent link: https://www.econbiz.de/10015056157
In the literature, it is widely discussed whether the pharmaceutical industry is going through an innovation crisis. Unfortunately, no comprehensive review exists to date that outlines the main empirical findings. In this paper, we provide an extensive survey on what is currently known about the...
Persistent link: https://www.econbiz.de/10014501658
This paper investigates the determinants of success in the development of new drugs. In specific, it explores the factors of success in drug development programs at different stages of innovation process. We use economies of scale, scope, R&D competition and technological spillovers as...
Persistent link: https://www.econbiz.de/10010270028
position of the US as a locus of innovation in pharmaceuticals has increased over the past decade compared to Europe. All in … in pharmaceuticals: 1) The size and the structure of the biomedical education and research systems; 2) Some basic …
Persistent link: https://www.econbiz.de/10005034968